Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C30H26F6N4O2 |
Molar mass | 588.554 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Antrafenine (Stakane) is a phenylpiperazine derivative drug invented in 1979. It acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen, but is not widely used as it has largely been replaced by newer drugs.
Synthesis
Method E: The reaction between 2--1-piperazinyl]ethanol (1) and Isatoic anhydride (2) goes on to give 4-(3-(Trifluoromethyl)phenyl)piperazine-1-ethyl 2-aminobenzoate (3).
Method G: Alkylation with 4-chloro-7-(trifluoromethyl)quinoline (4) completed the synthesis of antrafenine (5).
See also
References
- ^ Manoury PM, Dumas AP, Najer H, Branceni D, Prouteau M, Lefevre-Borg FM (May 1979). "Synthesis and analgesic activities of some (4-substituted phenyl-1-piperazinyl)alkyl 2-aminobenzoates and 2-aminonicotinates". Journal of Medicinal Chemistry. 22 (5): 554–9. doi:10.1021/jm00191a017. PMID 458805.
- Leatham PA, Bird HA, Wright V, Seymour D, Gordon A (1983). "A double blind study of antrafenine, naproxen and placebo in osteoarthrosis". European Journal of Rheumatology and Inflammation. 6 (2): 209–11. PMID 6673985.
- Don Pierre Rene Lucien Giudicelli, et al. U.S. patent 4,017,623 (1977 to Synthelabo SA).
- Don Pierre Rene Lucien Giudicelli, et al. U.S. patent 3,935,229 (1976 to Synthelabo SA).
- Don Pierre Rene Lucien Giudicelli, et al. U.S. patent 3,953,449 (1976 to Synthelabo SA).
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) | |
---|---|
pyrazolones / pyrazolidines | |
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use. | |
Prostanoid signaling modulators | |||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor (ligands) |
| ||||||||||||||||||||||||||
Enzyme (inhibitors) |
| ||||||||||||||||||||||||||
Others | |||||||||||||||||||||||||||
Piperazines | |
---|---|
Simple piperazines (no additional rings) | |
Phenylpiperazines |
|
Benzylpiperazines | |
Diphenylalkylpiperazines (benzhydrylalkylpiperazines) |
|
Pyrimidinylpiperazines | |
Pyridinylpiperazines | |
Benzo(iso)thiazolylpiperazines | |
Tricyclics (piperazine attached via side chain) |
|
Others/Uncategorized |
This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |